How I do it: Apalutamide use in non-metastatic castrate resistant prostate cancer.
Abstract
Urologists have been using oral nonsteroidal antiandrogens (AA) for 30 years as a
component of combined androgen blockade. In February 2018, a new third generation
AA, apalutamide, became available for the first time for non-metastatic (M0) castrate
resistant prostate cancer (CRPC). Apalutamide was found to delay the presence of metastases
(metastases free survival-MFS) by approximately 2 years versus placebo in M0 CRPC.
While overall survival benefit has yet to be established, the MFS benefit is clinically
meaningful and urology practices should be equipped to manage patients using this
new oral agent. Since the majority of patients remain under urologic care when this
disease stage develops and because the drug is straightforward to administer, urology
practices are ideal to identify and treat. The objective of this brief article is
to discuss the typical patient profile for use of apalutamide and to review the pros
and cons of use and common side effects and management.
Type
Journal articlePermalink
https://hdl.handle.net/10161/19059Collections
More Info
Show full item recordScholars@Duke
Judd Wendell Moul
James H. Semans, M.D. Distinguished Professor of Urologic Surgery, in the School of
Medicine
Dr Judd Moul joined the Duke faculty in mid 2004 after a career in the US Army Medical
Corps mainly at Walter Reed Army Medical Center. He is a retired colonel and a noted
researcher and clinician in the area of prostate cancer and is a urologic oncologist.
He served as the division chief of Duke Division of Urology from 2004 to 2011 and
was named the James H Semans MD Professor of surgery in 2009 becoming Duke's first
named endowed chair for urology. He was awarded the Gold Cystosco

Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info